REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
/ 17 items
#XY Earnings Movers↓
Hims & Hers Q1 2026 Earnings: Big Subscriber Jump But Misses Estimates – Raises Full-Year Outlook
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.
PTC Therapeutics Beats Wall Street Estimates and Hikes 2026 Outlook on Strong Sephience Launch
PTC beat estimates, Sephience sales surged, losses small, outlook raised, and analysts upgraded stock on strong growth momentum.
Sarepta Therapeutics Q1 2026 Earnings: Big Beat, But Stock Still Falls
Sarepta reported strong Q1 2026 earnings, with revenue of $730.8M, but shares fell as Elevidys sales dropped 46% due to label restrictions.
Oscar Health Just Had Its Most Profitable Quarter Ever
Oscar Health posted record profit, strong growth, and lower costs, showing a major turnaround and fast expansion.
Novavax Smashes Q1 2026 Revenue Expectations with Big Vaccine Tech Deals
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.